AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group
Source: View publication →
In pediatric and young adult patients with newly diagnosed acute myeloid leukemia, induction therapy with liposomal daunorubicin-cytarabine (CPX-351) was inferior to standard daunorubicin and cytarabine, driven largely by increased relapse rates and inferior event-free survival in low-risk patients.
Key Findings
Study Design
Study Limitations
Clinical Significance
The AAML1831 trial unequivocally demonstrates that CPX-351 should not replace standard daunorubicin and cytarabine (DA) for induction therapy in pediatric and young adult patients with de novo AML. Despite CPX-351's established superiority in older adults with therapy-related or secondary AML, its use in the pediatric de novo population led to increased toxicity, higher relapse rates, and compromised event-free survival. These findings reinforce standard DA combined with gemtuzumab ozogamicin as the standard-of-care induction backbone for pediatric AML.
Historical Context
Historically, pediatric acute myeloid leukemia outcomes plateaued as the intensification of conventional anthracycline and cytarabine regimens reached limits of unacceptable cardiotoxicity and treatment-related mortality. CPX-351, a liposomal 5:1 molar ratio formulation of cytarabine and daunorubicin, demonstrated superior overall survival and a favorable pharmacokinetic profile in adults with therapy-related AML and AML with myelodysplasia-related changes, leading to its FDA approval in 2017. The Children's Oncology Group designed AAML1831 hypothesizing that CPX-351 would enhance anti-leukemic efficacy while mitigating cardiotoxicity in pediatric de novo AML. Strikingly, the trial revealed that the biology of pediatric de novo AML responds differently than adult secondary AML, failing to achieve the same therapeutic benefits.
Guided Discussion
High-yield insights from every perspective
What is the pharmacological rationale behind using CPX-351 (liposomal cytarabine and daunorubicin) in acute myeloid leukemia, and how does its delivery mechanism theoretically differ from standard '7+3' induction?
Key Response
CPX-351 encapsulates cytarabine and daunorubicin in a synergistic 5:1 molar ratio within a liposome. Theoretically, this allows for a prolonged half-life, preferential accumulation in the bone marrow, and direct uptake by leukemia cells. While this proved effective in secondary/therapy-related adult AML, it paradoxically failed to improve outcomes in de novo pediatric AML in this trial.
Given the results of the AAML1831 trial, how should you counsel the family of a newly diagnosed pediatric patient with low-risk AML regarding their induction chemotherapy options?
Key Response
Residents must know that standard daunorubicin and cytarabine remains the standard of care for de novo pediatric AML. The trial showed CPX-351 was inferior, specifically driven by higher relapse rates and worse event-free survival in the low-risk subgroup, meaning off-label use of CPX-351 in this population could be harmful and standard induction should be strongly recommended.
The AAML1831 trial demonstrated the inferiority of CPX-351 largely in the low-risk pediatric AML cohort. What are the potential biological or pharmacokinetic reasons that a liposomal formulation might underperform specifically in low-risk de novo disease compared to its known efficacy in high-risk, secondary adult AML?
Key Response
Low-risk pediatric AML (often driven by core-binding factor translocations) may have rapid proliferation kinetics requiring the high peak plasma concentrations achieved by standard bolus/infusion rather than the prolonged, lower-level release of liposomal CPX-351. Furthermore, secondary adult AMLs often have MDR1 efflux pumps that liposomes bypass; de novo pediatric AMLs typically lack these, negating the liposomal advantage.
This trial highlights a classic 'failure to translate' from adult to pediatric oncology. How does the unexpected inferiority of CPX-351 in AAML1831 reshape our approach to adopting adult FDA-approved targeted or novel therapies for pediatric leukemias outside of clinical trials?
Key Response
Attendings must synthesize broader practice implications. CPX-351's success in older adults with secondary AML led to enthusiasm for its use. Its failure in pediatric de novo AML underscores that pediatric AML has distinct genomic landscapes and pharmacokinetic tolerability. It teaches the vital lesson that adult data cannot be blindly extrapolated to pediatrics, reinforcing the necessity of cooperative group trials like COG before changing standard pediatric regimens.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In phase III non-inferiority or superiority trials like AAML1831, how does the inclusion of diverse risk-stratified cohorts (low, standard, high risk) complicate the statistical powering and interim analysis plans when an intervention exhibits divergent efficacy, such as harm in the low-risk subgroup?
Key Response
Researchers must consider trial design. If an intervention behaves differently across strata (interaction effect), the trial may halt early for harm in one subgroup (low-risk) while lacking power to definitively answer the question for the high-risk group. Designing such trials requires robust hierarchical or stratified alpha-spending strategies to prevent early termination from confounding the results of potentially benefiting subgroups.
As a reviewer evaluating the AAML1831 manuscript, what specific confounding variables regarding post-induction therapy (e.g., rates of hematopoietic stem cell transplant, consolidation regimens) would you require the authors to detail to ensure the observed EFS difference is entirely attributable to the induction phase?
Key Response
Editors must look for post-randomization confounding. Even though induction is the intervention, EFS and relapse are influenced by post-remission strategies. If patients receiving CPX-351 had different rates of proceeding to transplant, minimal residual disease (MRD)-guided therapy modifications, or delayed count recovery affecting consolidation timing, these factors could artificially drive the inferior outcomes rather than the induction drug alone.
Based on the AAML1831 results, how should pediatric oncology guidelines explicitly position CPX-351 for de novo pediatric AML, and what level of evidence does this trial provide against its use?
Key Response
This is a large, randomized Phase III cooperative group trial providing Level 1 evidence of inferiority. Guidelines (e.g., NCCN or COG consensus pathways) must explicitly recommend against the use of CPX-351 as initial induction therapy for de novo pediatric AML, preserving standard anthracycline/cytarabine-based induction as a Category 1 recommendation and specifically highlighting the risk of increased relapse in low-risk disease.
Clinical Landscape
Noteworthy Related Trials
AAML0531 Trial
Tested
Gemtuzumab ozogamicin + standard chemotherapy
Population
De novo pediatric AML
Comparator
Standard chemotherapy alone
Endpoint
Event-free survival
AAML1031 Trial
Tested
Bortezomib + standard chemotherapy
Population
De novo pediatric AML
Comparator
Standard chemotherapy alone
Endpoint
Event-free survival
Study 301
Tested
CPX-351
Population
Older adults with secondary AML
Comparator
7+3 cytarabine and daunorubicin
Endpoint
Overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis